CD8A and pancreatic neoplasm: have shown that targeting glutamine‐utilizing enzymes using a glutamine analog (6‐diazo‐5‐oxo‐l‐norleucine) can remodel the extracellular matrix (ECM) and elevate infiltration of CD8+ T cells, leading to sensitization of pancreatic cancer to anti‐PD1 therapy.